# TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma

Source: https://onco.cc/trials/nct07862647/  
OnCo record `nct07862647` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of PoMA sonodynamic therapy run by Alpheus Medical, Inc., now recruiting.

## Summary

TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma is a phase 1 interventional study registered as NCT07862647 by Alpheus Medical, Inc., with 30 participants planned, started 2026-10-29, primary completion expected 2027-10-30. Conditions recorded: Glioblastom WHO Grade 4, GBM, bGBM, Butterfly GBM, Bihemispheric GBM, Glioblastoma. Interventions recorded: 5-ALA, Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07862647
- Phase: 1
- Setting: A Phase 1 Clinical Trial Evaluating the Safety and Tolerability of Bilateral Hemispheric 5-ALA-Mediated Sonodynamic Therapy Using the LIDU System Before Standard Radiochemotherapy and During Adjuvant Temozolomide in Patients With Histologically Proven Newly Diagnosed Butterfly Glioma
- Sponsor: Alpheus Medical, Inc.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07862647: https://clinicaltrials.gov/study/NCT07862647

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [PoMA sonodynamic therapy](https://onco.cc/drugs/poma-sonodynamic-therapy/)
- companies: [Alpheus Medical](https://onco.cc/companies/alpheus-medical/)

---
JSON: https://onco.cc/api/v1/entities/nct07862647.json